{"key":"op_800_IT","page":{"url":"https://fr.bookimed.com/clinics/country=italy/procedure=car-t-cell-therapy/","procedure":{"id":800,"slug":"car-t-cell-therapy","name":"Thérapie CAR T","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"hematology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":127,"iso":"IT","name":"Italie"},"currency":"USD","data_date":"2026-09-25"},"pages":{"clinics_url":"https://fr.bookimed.com/clinics/country=italy/procedure=car-t-cell-therapy/","cost_url":"https://fr.bookimed.com/clinics/country=italy/procedure=car-t-cell-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":400000,"to":650000,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":420000,"to":540000},"uk":{"from":330000,"to":420000},"by_technique":[{"technique":"Autologous CD19-directed CAR T-cell therapy","technique_id":"autologous-cd19-directed-car","price_from":400000,"currency":"USD","source":"estimate","date":"2026-11-17"},{"technique":"Autologous BCMA-directed CAR T-cell therapy","technique_id":"autologous-bcma-directed-car","price_from":480000,"currency":"USD","source":"estimate","date":"2026-11-17"}],"by_city":[{"city":"Milan","from":400000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":90000,"to":150000},{"country_iso":"FR","from":295000,"to":385000},{"country_iso":"GB","from":330000,"to":420000},{"country_iso":"US","from":420000,"to":540000},{"country_iso":"IL","from":84000,"to":405000},{"country_iso":"TR","from":150000,"to":220000},{"country_iso":"MX","from":120000,"to":185000},{"country_iso":"DE","from":285000,"to":365000},{"country_iso":"CA","from":340000,"to":470000},{"country_iso":"AE","from":190000,"to":310000},{"country_iso":"TH","from":150000,"to":220000},{"country_iso":"PL","from":165000,"to":230000},{"country_iso":"KR","from":220000,"to":300000},{"country_iso":"CZ","from":150000,"to":195000},{"country_iso":"AT","from":280000,"to":365000},{"country_iso":"ES","from":380000,"to":520000},{"country_iso":"CN","from":275000,"to":310000},{"country_iso":"AU","from":330000,"to":420000},{"country_iso":"IN","from":38000,"to":70000},{"country_iso":"MY","from":120000,"to":180000},{"country_iso":"VN","from":150000,"to":230000},{"country_iso":"BR","from":280000,"to":400000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":5,"variant":"ranges_overlap"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":2,"items":[{"id":298,"name":"San Donato Hospital","city":"Milan","rating":4.8,"reviews_count":55,"accreditations":["Scientific Institute for Research and Healthcare Accrediatation","World's Best Hospitals 2021 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"Offers CAR T-cell therapy with a dedicated international department for patient coordination. Part of Gruppo Ospedaliero San Donato, known for research in oncology.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":303,"name":"San Raffaele","city":"Milan","rating":4.6,"reviews_count":71,"accreditations":["Scientific Institute for Research and Healthcare Accrediatation","World's Best Hospitals 2021 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Performs over 140 bone marrow transplants annually, with specialists like Prof. Fabio Ciceri leading CAR T-cell therapy trials. 60% of transplants are allogeneic, indicating advanced capabilities.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":1,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":353,"slug":"milan","name":"Milan","clinics_count":1,"price_from":400000,"profile":{"city_type":"Capital and largest city of Lombardy","access":["Malpensa Airport (MXP), 49 km from Milan","Linate Airport (LIN), 7 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Milan","https://en.wikipedia.org/wiki/Milan_Malpensa_Airport","https://en.wikipedia.org/wiki/Linate_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"hospital_nights":{"value":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"source":"parsed_details"},"treatment_conditions":["inpatient"],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"horizon":"Best response, typically assessed at 1-3 months after infusion","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Complete blood count","aliases":["Complete blood count","CBC","Full blood count"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"},{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Biopsy","aliases":["Biopsy","Bone marrow biopsy"],"kind":"other","origin":[{"field":"initial_assessment_documents","text":"Bone marrow biopsy report"},{"field":"packages","text":"Biopsy"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"PET-CT scan","aliases":["PET-CT scan","PET-CT","PET/CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"PET/CT"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"MRI scan","aliases":["MRI scan","MRI","Head MRI"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"Head MRI"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Echocardiogram","aliases":["Echocardiogram","Echocardiography"],"kind":"heart","origin":[{"field":"initial_assessment_documents","text":"Echocardiogram report (if available)"},{"field":"packages","text":"Echocardiography"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Kidney function test","aliases":["Kidney function test","Kidney function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Liver function test","aliases":["Liver function test","Liver function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"Tumor marker test","aliases":["Tumor marker test","Cancer markers"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T10","name":"Serum protein electrophoresis","aliases":["Serum protein electrophoresis","Proteinogram"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"prep_in_advance":{"status":"ok","items":[{"id":"P1","action":"Ask your team whether chemotherapy or radiation will be given before the T cells are returned to you","why":"The treatment aims to get rid of other immune cells","who_decides":"prescriber","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"During this time, you may have treatment with chemotherapy and, maybe, radiation therapy to get rid of other immune cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"visit_and_day":{"status":"ok","has_procedure_day":true,"items":[{"id":"V1","text":"The CAR T-cell product is sent back to the hospital and returned to the patient as a single infusion","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"These expanded cells are the final CAR T-cell therapy product, which is sent back to the hospital to be returned to the patient as a single infusion.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},{"id":"V2","text":"The T cells grown in the lab are given back to the patient through a needle in a vein","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"After these treatments, the T cells that were grown in the lab will be given back to you via a needle in your vein.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"days_in_clinic":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","revision_rate_pct":null,"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"unit":"percent","horizon":"Best response, typically assessed at 1-3 months after infusion","evidence_status":"limited","population":"Adults with relapsed/refractory LBCL after two or more prior lines"},"techniques":[{"name":"Autologous CD19-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"name":"Autologous BCMA-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","recovery":"Similar monitoring; prolonged cytopenias are common."}],"treatment_conditions":["inpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"initial_assessment_documents":["Pathology report with CD19 or BCMA status","Summary of prior treatment lines and responses","Recent PET-CT or MRI report","Bone marrow biopsy report","Recent CBC, kidney and liver function tests","Echocardiogram report (if available)"],"travel_trips":{"min":1,"max":2,"one_trip_possible":true,"qualifier":"Cell collection, then 3-9 weeks manufacturing, usually at home; return for infusion and 4+ weeks nearby. One trip means staying."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Complete blood count","aliases":["Complete blood count","CBC","Full blood count"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"},{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Biopsy","aliases":["Biopsy","Bone marrow biopsy"],"kind":"other","origin":[{"field":"initial_assessment_documents","text":"Bone marrow biopsy report"},{"field":"packages","text":"Biopsy"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"PET-CT scan","aliases":["PET-CT scan","PET-CT","PET/CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"PET/CT"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"MRI scan","aliases":["MRI scan","MRI","Head MRI"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"Head MRI"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Echocardiogram","aliases":["Echocardiogram","Echocardiography"],"kind":"heart","origin":[{"field":"initial_assessment_documents","text":"Echocardiogram report (if available)"},{"field":"packages","text":"Echocardiography"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Kidney function test","aliases":["Kidney function test","Kidney function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Liver function test","aliases":["Liver function test","Liver function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"Tumor marker test","aliases":["Tumor marker test","Cancer markers"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T10","name":"Serum protein electrophoresis","aliases":["Serum protein electrophoresis","Proteinogram"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"prep_in_advance":{"status":"ok","items":[{"id":"P1","action":"Ask your team whether chemotherapy or radiation will be given before the T cells are returned to you","why":"The treatment aims to get rid of other immune cells","who_decides":"prescriber","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"During this time, you may have treatment with chemotherapy and, maybe, radiation therapy to get rid of other immune cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"visit_and_day":{"status":"ok","has_procedure_day":true,"items":[{"id":"V1","text":"The CAR T-cell product is sent back to the hospital and returned to the patient as a single infusion","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"These expanded cells are the final CAR T-cell therapy product, which is sent back to the hospital to be returned to the patient as a single infusion.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},{"id":"V2","text":"The T cells grown in the lab are given back to the patient through a needle in a vein","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"After these treatments, the T cells that were grown in the lab will be given back to you via a needle in your vein.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}}},"techniques":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","price_from":400000,"recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","price_from":480000,"recovery":"Similar monitoring; prolonged cytopenias are common."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK passport holders can travel to Italy without a visa for up to 90 days in any 180-day period","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/entry-requirements","host":"gov.uk","quote":"You can travel without a visa to the Schengen area , which includes Italy, for up to 90 days in any 180-day period.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"U.S. citizens may enter Italy without a visa for up to 90 days for tourist or business purposes","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"U.S. citizens may enter Italy for up to 90 days for tourist or business purposes without a visa.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 3 months after the day you plan to leave the Schengen area","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/entry-requirements","host":"gov.uk","quote":"have an ‘expiry date’ at least 3 months after the day you plan to leave the Schengen area (the expiry date does not need to be within 10 years of the date of issue)","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A U.S. passport must be valid for at least 3 months beyond the period of stay in Italy","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"Your passport must be valid for at least 3 months beyond the period of stay.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"all","volatile":false,"text":"Foreigners may bring personal medications for 30 days into Italy; bringing a copy of the prescription is recommended","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"According to the Ministry of Health, foreigners entering Italy are allowed to bring personal medications for a period of 30 days, but it is recommended that travelers also bring a copy of their prescription with them.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"ghic","audience":"uk","volatile":false,"text":"A UK GHIC or EHIC is needed to get medically necessary state healthcare in Italy","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/health","host":"gov.uk","quote":"To get medically necessary state healthcare in Italy, you need a Global Health Insurance Card ( GHIC ) or a European Health Insurance Card ( EHIC ).","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V7","item":"hospital_payment","audience":"all","volatile":false,"text":"Private hospitals in Italy usually require advance payment or proof of adequate insurance before admitting a patient","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"Private hospitals usually require advance payment or proof of adequate insurance before admitting a patient.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V8","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 118 and ask for an ambulance in Italy","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/health","host":"gov.uk","quote":"Dial 118 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","china","germany","israel","lithuania","republic-of-korea","spain","thailand","turkey","united-kingdom","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.69,"count":126,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>CAR T-cell therapy in Italy typically costs from _op_800_price_from_ to _op_800_price_to_ for the full clinical pathway. The final price depends on the specific drug product, duration of mandatory hospital monitoring, and management of potential side effects. Patients save approximately _price_percent_discount_% compared to the US, where this treatment averages _price_compare_US_average_. Most Italian protocols include cell collection, laboratory manufacturing, and specialized inpatient care in Milan or Rome.</p>\n\n<ul>\n<li><strong>Pharmaceutical product:</strong> Usually accounts for approximately 75% of the total treatment budget.</li>\n<li><strong>Clinical procedures:</strong> Covers leukapheresis for cell collection and cryopreservation of the modified cells.</li>\n<li><strong>Hospital stay:</strong> Includes 14 to 25 days of specialized inpatient monitoring for safety.</li>\n<li><strong>Complication management:</strong> Serious adverse events like Cytokine Release Syndrome may add 15-20% to costs.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing a research-heavy center like San Raffaele in Milan provides access to world-renowned hematologists like Prof. Fabio Ciceri. This clinic, recognized by Newsweek as one of the World's Best Hospitals, offers CAR T-cell therapy starting around $140,150. While this base price covers the essential procedure, staying in an IRCCS-accredited facility ensures the highest standards for managing complex genetic and immune-related cases.</p>","faq":[{"q":"Is CAR T-cell therapy available in Italy?","a":"<p>CAR T-cell therapy is available in Italy as a standard treatment for relapsed or refractory hematological malignancies like lymphoma and leukemia. The Italian Medicines Agency (AIFA) regulates these therapies, which are primarily delivered through specialized IRCCS-accredited research hospitals and university clinics.</p> <ul> <li><strong>Approved treatments:</strong> Facilities offer advanced CAR T products including Kymriah (tisagenlecleucel) and Carvykti.</li> <li><strong>Leading centers:</strong> Major hubs include San Raffaele in Milan and Bambino Gesù in Rome.</li> <li><strong>Eligibility criteria:</strong> AIFA recently raised the age limit to 75 years for certain indications.</li> <li><strong>Cost range:</strong> Full clinical pathways for international patients range from _op_800_price_from_ to _op_800_price_to_.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While northern Italy clinics like San Raffaele handle the highest patient volumes, data shows a trend where centers in southern Italy, such as Cardarelli Hospital in Naples, may offer faster navigation through administrative bureaucracy. Patients should compare wait times across regions, as northern hubs often face higher demand despite having more facilities.</p> <p><strong>Patient Consensus:</strong> Seeking treatment early is vital as intensive prior chemotherapy can impact eligibility. Patients frequently note that the pre-approval process is rigorous and may require several months of waiting.</p>"},{"q":"Who is eligible for CAR T-cell therapy in Italy?","a":"<p>Eligibility for CAR T-cell therapy in Italy requires patients to have relapsed or refractory hematological cancers. Candidates must fail at least two prior lines of systemic therapy. The Italian Medicines Agency governs access through specialized hub centers like San Raffaele in Milan.</p> <ul> <li><strong>Disease status:</strong> Limited to refractory lymphoma, leukemia, or myeloma after standard treatments fail.</li> <li><strong>Age requirements:</strong> Patients up to 75 years for lymphoma and 25 for leukemia.</li> <li><strong>Physical fitness:</strong> Requires ECOG status 0–1 and adequate heart, kidney, and lung function.</li> <li><strong>Life expectancy:</strong> Candidates must have a projected life expectancy of at least 12 weeks.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While Italy follows European Medicines Agency standards, the Italian Medicines Agency often sets stricter age caps. Professor Fabio Ciceri at San Raffaele leads critical cell therapy trials that may offer earlier access. Patients often wait 3–6 months for manufacturing, so early referral to a hub is vital.</p> <p><strong>Patient Consensus:</strong> Many find the approval process rigorous and sometimes describe it as a lottery. Moving quickly between treatment lines is essential to remain healthy enough for the manufacturing period.</p>"},{"q":"Is CAR T-cell therapy covered by the Italian healthcare system?","a":"<p>Italy's national healthcare system (Servizio Sanitario Nazionale) fully covers CAR T-cell therapy for eligible patients. The Italian Medicines Agency (AIFA) grants these treatments innovation status, meaning public funding applies at authorized hematology centers for specific relapsed or refractory B-cell malignancies and multiple myeloma.</p> <ul> <li><strong>Approved indications:</strong> Covers B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma.</li> <li><strong>Clinical criteria:</strong> Patients must have failed at least two lines of prior systemic therapy.</li> <li><strong>Authorized centers:</strong> Treatment occurs at specialized IRCCS-accredited facilities like Ospedale San Raffaele in Milan.</li> <li><strong>Age limits:</strong> Coverage extends to patients up to 75 years for specific approved therapies.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While Italy offers full public coverage, the concentration of authorized centers in Lombardy and Lazio creates significant geographic disparities. Patients often choose San Raffaele because it combines IRCCS research accreditation with massive clinical volume, serving 300,000 patients annually. This helps navigate the complex AIFA drug registry requirements faster than smaller regional hospitals.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that while treatment is free for citizens, the approval process can take 6 months. Many suggest starting the eligibility verification early at AIFA-approved centers to manage the 3-to-12 month waiting periods effectively.</p>"},{"q":"Which hospitals in Italy are leading CAR T-cell therapy centers?","a":"<p>Italy is a global leader in CAR T-cell therapy, with San Raffaele in Milan and Bambino Gesù Children Hospital in Rome serving as primary hubs. These AIFA-authorized centers specialize in cell and gene therapy clinical trials for adult hematology and pediatric neuroblastoma.</p> <ul> <li><strong>San Raffaele Milan:</strong> Primary adult hub led by Professor Fabio Ciceri for complex hematological cancers.</li> <li><strong>Bambino Gesù Rome:</strong> Global leader in pediatric immunotherapy and neuroblastoma CAR-T treatment development.</li> <li><strong>Careggi University Hospital:</strong> Authorized academic center providing licensed therapies like Yescarta and Kymriah.</li> <li><strong>Humanitas Research Hospital:</strong> Specialized oncology institute focusing on advanced immunotherapy protocols for lymphoma.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data shows San Raffaele maintains a unique position by integrating world-first stem cell breakthroughs with CAR-T delivery. While many centers offer standard protocols, Milan's IRCCS-accredited facilities manage significantly higher patient volumes. This concentrated experience often leads to more robust multidisciplinary follow-up for complex immune responses.</p>"},{"q":"What are the main barriers to accessing CAR T-cell therapy in Italy?","a":"<p>Accessing CAR T-cell therapy in Italy is hindered by uneven geographic distribution of centers, complex regional reimbursement processes, and strict eligibility criteria. While AIFA-approved, 70% of qualified clinics are concentrated in four northern and central regions, leaving five southern regions without local access.</p> <ul> <li><strong>Geographic disparities:</strong> Treatment hubs are limited to cities like Milan and Rome, requiring patient relocation.</li> <li><strong>Reimbursement delays:</strong> Transitioning from national to regional funding creates administrative bottlenecks and lengthy local appeals.</li> <li><strong>Regulatory bottlenecks:</strong> AIFA often maintains stricter age and fitness limits than standard EMA guidelines.</li> <li><strong>Referral fragmentation:</strong> Lack of a national referral system causes delays in identifying eligible patients.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While standard CAR T pathways involve long waits, Milan remains the strategic choice for international and local patients. Clinics like San Raffaele combine massive clinical research with high-volume hematology departments. Their role in gene therapy trials often provides earlier access to technology than smaller regional centers.</p> <p><strong>Patient Consensus:</strong> Patients report that while public coverage exists, the 6 to 12-month wait times often necessitate early involvement of advocacy groups. Most recommend securing complete treatment documentation immediately to expedite the complex reimbursement appeals process.</p>"}],"h2":[{"text":"Comment ça fonctionne","kind":"content"},{"text":"Quel est le Coût pour votre Thérapie CAR T en Italie ?","kind":"content"},{"text":"Découvrez les Meilleures Cliniques pour Votre Thérapie CAR T en Italie : 2 Options Vérifiées et Prix","kind":"content"},{"text":"Aperçu de thérapie CAR T en Italie","kind":"content"},{"text":"Obtenez une évaluation médicale pour Thérapie CAR T en Italie : Choisissez le meilleur spécialiste dans le domaine","kind":"content"},{"text":"Partager ce contenu","kind":"content"},{"text":"Histoires vidéo des patients de Bookimed","kind":"content"},{"text":"FAQ de thérapie CAR T en Italie","kind":"content"},{"text":"Obtenez une consultation gratuite","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}